AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
- AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
- FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions
- Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
- Bayer selects Pharmaron as partner organization
Research & Development
- The gut may be involved in the development of multiple sclerosis
- Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer
- Investigational drugs reduce risk of death from Ebola virus disease
- Pharmacist-led interventions may help prevent cardiovascular disease
- A protein tag to study the immune system
- Industry executives: Profits drive rising prices for MS drugs
- Artificial Intelligence algorithm can learn the laws of quantum mechanics and speed up drug delivery
Conferences & Events
- Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020
- SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020
- SMi's 4th Annual 3D Cell Culture
- Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
- RNA Therapeutics Conference and Focus Day
- CPhI Worldwide announces the winners of the 16th Pharma Awards
- CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023
Regulatory Affairs
- FDA approves first generics of Gilenya
- FDA approves novel treatment to target abnormality in sickle cell disease
- FDA approves first treatment for inherited rare disease
- FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
- FDA approves first therapy to treat patients with rare blood disorder